ArticlePediatric nephrology (Berlin, Germany)2010
Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.
Article in Pediatric nephrology (Berlin, Germany), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 5 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children.Frontiers in pediatrics · 2021Pooled it
- The efficacy of rituximab in the treatment of refractory nephrotic syndrome: a meta-analysis.International urology and nephrology · 2020Pooled it
- Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis.Medicine · 2016Pooled it
- The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis.Scientific reports · 2015Pooled it
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.Clinical and experimental nephrology · 2015Guideline
- Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.Medicine · 2018Trial
- Trial
- Trial
- Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2015Trial
- Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.Journal of the American Society of Nephrology : JASN · 2014Trial
- A case of anti-nephrin antibody-positive, steroid-dependent nephrotic syndrome with successful discontinuation of immunosuppressants following rituximab.Oxford medical case reports · 2026Article
- Subcutaneous ofatumumab for remission maintenance in pediatric idiopathic nephrotic syndrome: a case series.Clinical kidney journal · 2026Article
- [Efficacy and safety of rituximab in children with refractory nephrotic syndrome].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndrome.World journal of pediatrics : WJP · 2025Review
- Risk factors and retreatment for relapse in childhood primary nephrotic syndrome treated with rituximab.Pediatric nephrology (Berlin, Germany) · 2025Article
- Efficacy and safety of rituximab in children with steroid-dependent or frequently relapsing nephrotic syndrome: a meta-analysis of randomized controlled trials.Archives of medical science : AMS · 2025Review
- Efficacy and Safety of Rituximab in Treating Adult Patients with Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Prospective Study Compared with Glucocorticoids.Drug design, development and therapy · 2025Article
- TRPC6 knockdown-mediated ERK1/2 inactivation alleviates podocyte injury in minimal change disease via upregulating Lon peptidase 1.Renal failure · 2024Article
- Long Term Evaluations of First Single-dose Rituximab in Children with Steroid-Dependent Minimal-Change Nephrotic Syndrome.Renal failure · 2024Observational
- Adult survivors of childhood-onset steroid-dependent and steroid-resistant nephrotic syndrome treated with cyclosporine: a long-term single-center experience.Pediatric nephrology (Berlin, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (RTX) has been successfully used as a rescue therapy in children with steroid-dependent nephrotic syndrome (SDNS). However, little is known regarding maintenance therapy after a successful response to RTX in such patients. The efficacy and safety of a single RTX infusion (375 mg/m(2)) were assessed in ten patients who had persistent SDNS associated with minimal-change disease (MCD) despite the long-term use of cyclosporine (CsA). The mean follow-up after RTX infusion was 17 months. Applying RTX resulted in a significant reduction in the mean prednisolone (PSL) dose from 0.39 +/-0.18 to 0.15 +/- 0.14 mg/kg per day. The mean 12-month relapse rates significantly decreased from 4.1 +/- 1.7 to 0.6 +/- 0.6. All but one patient who had continued CsA as maintenance therapy after a single RTX infusion were able to withdraw from PSL without any relapses during the study period, whereas the remaining five patients who discontinued CsA experienced relapses after CD19 cells re-emerged, leading to the reintroduction of CsA or an additional RTX infusion. Infusion reactions occurred in five of ten patients. These data indicate that a single RTX infusion may improve response to CsA in patients with persistent SDNS due to the phenomenon of secondary resistance to CsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.